Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 3/20 | 0.43 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.42 |
| ▸ | REN | P00797 | 1/20 | 0.42 |
| ▸ | KRAS | P01116 | 6/20 | 0.41 |
| ▸ | CTSB | P07858 | 1/20 | 0.41 |
| ▸ | CTSK | P43235 | 1/20 | 0.41 |
| ▸ | RXFP4 | Q8TDU9 | 2/20 | 0.40 |
| ▸ | RXFP3 | Q9NSD7 | 2/20 | 0.40 |
| ▸ | VIPR1 | P32241 | 1/20 | 0.40 |
| ▸ | VIPR2 | P41587 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4082674 | 0.93 | OPRM1 (0.46) | KEAP1RENCTSBCTSKRXFP4 | |
| SCHEMBL4086167 | 0.92 | PSEN1 (0.41) | NPY4RKEAP1 | |
| SCHEMBL4092691 | 0.91 | KRAS (0.42) | NPY4RKEAP1RENKRASCTSB | |
| SCHEMBL4255374 | 0.89 | REN (0.41) | KEAP1RENKRASCTSBCTSK | |
| SCHEMBL4089292 | 0.89 | OPRM1 (0.48) | KEAP1RENCTSBCTSKRXFP4 | |
| SCHEMBL4087936 | 0.89 | KRAS (0.41) | NPY4RKEAP1RENKRASCTSB | |
| SCHEMBL4082481 | 0.87 | OPRM1 (0.45) | RENCTSBCTSKRXFP4RXFP3 | |
| SCHEMBL4088339 | 0.87 | KISS1R (0.49) | KRASVIPR1VIPR2 | |
| SCHEMBL4082466 | 0.87 | KRAS (0.43) | KEAP1KRASVIPR1VIPR2 | |
| SCHEMBL2367102 | 0.87 | KEAP1 (0.50) | NPY4RKEAP1VIPR1VIPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8076285-B2 | Lysobactin amides | AICURIS GMBH & CO. KG (DE) | 2011-12-13 | — | — | US | disclosed |
| EP-2007794-B1 | LYSOBACTIN AMIDES | AICURIS GMBH & CO KG (DE) | 2011-09-14 | — | — | EP | disclosed |
| US-20090203582-A1 | LYSOBACTIN AMIDES | BAYER HEALTHCARE AG (DE) | 2009-08-13 | — | — | US | disclosed |
| EP-2007794-A1 | LYSOBACTIN AMIDES | AiCuris GmbH & Co. KG (DE) | 2008-12-31 | — | — | EP | disclosed |
| WO-2007118691-A1 | LYSOBACTIN AMIDES | AICURIS GMBH & CO. KG (DE) | 2007-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203582-A1 | LYSOBACTIN AMIDES | AADAT, HAMP, DLST | NPY4R 1014/4885KEAP1 2850/4885REN 1728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.